Abnormal Epidermal Barrier Recovery in Uninvolved Skin supports the Notion of an Epidermal Pathogenesis of Psoriasis

[1]  Hidetoshi Takahashi,et al.  Defective barrier function accompanied by structural changes of psoriatic stratum corneum , 2014, The Journal of dermatology.

[2]  M. Setou,et al.  Barrier abnormality due to ceramide deficiency leads to psoriasiform inflammation in a mouse model. , 2013, The Journal of investigative dermatology.

[3]  N. Muizzuddin,et al.  Effect of seasonal and geographical differences on skin and effect of treatment with an osmoprotectant: Sorbitol. , 2013, Journal of cosmetic science.

[4]  Joachim L. Schultze,et al.  Keratin 1 maintains skin integrity and participates in an inflammatory network in skin through interleukin-18 , 2012, Journal of Cell Science.

[5]  J. Schalkwijk,et al.  Genetics of psoriasis: evidence for epistatic interaction between skin barrier abnormalities and immune deviation. , 2012, The Journal of investigative dermatology.

[6]  M. Széll,et al.  The psoriatic keratinocytes , 2012 .

[7]  E. Tschachler,et al.  TOPICAL ANTIHISTAMINES DISPLAY POTENT ANTI-INFLAMMATORY ACTIVITY LINKED IN PART TO ENHANCED PERMEABILITY BARRIER FUNCTION , 2012, The Journal of investigative dermatology.

[8]  Xuejun Zhang.  Genome-wide association study of skin complex diseases. , 2012, Journal of dermatological science.

[9]  H. Kwon,et al.  Epidemiology and clinical features of pediatric psoriasis in tertiary referral psoriasis clinic , 2012, The Journal of dermatology.

[10]  A. Irvine,et al.  Filaggrin mutations associated with skin and allergic diseases. , 2011, The New England journal of medicine.

[11]  C. Backendorf,et al.  ROS quenching potential of the epidermal cornified cell envelope. , 2011, The Journal of investigative dermatology.

[12]  M. Boguniewicz,et al.  TNF-α downregulates filaggrin and loricrin through c-Jun N-terminal kinase: role for TNF-α antagonists to improve skin barrier. , 2011, The Journal of investigative dermatology.

[13]  P. Elias.  Therapeutic Implications of a Barrier-based Pathogenesis of Atopic Dermatitis. , 2010, Annals of dermatology.

[14]  J. Sundberg,et al.  Filaggrin deficiency confers a paracellular barrier abnormality that reduces inflammatory thresholds to irritants and haptens. , 2009, The Journal of allergy and clinical immunology.

[15]  P. Elias,et al.  Chinese herbal medicine (Tuhuai extract) exhibits topical anti‐proliferative and anti‐inflammatory activity in murine disease models , 2008, Experimental dermatology.

[16]  Hee-Ryung Cho,et al.  A Study on Altered Expression of Serine Palmitoyltransferase and Ceramidase in Psoriatic Skin Lesion , 2007, Journal of Korean medical science.

[17]  V. Rogiers,et al.  Sustained serine proteases activity by prolonged increase in pH leads to degradation of lipid processing enzymes and profound alterations of barrier function and stratum corneum integrity. , 2005, The Journal of investigative dermatology.

[18]  M. Denda,et al.  Dry environment increases mast cell number and histamine content in dermis in hairless mice , 2003, The British journal of dermatology.

[19]  M. Denda,et al.  Epidermal interleukin‐1α generation is amplified at low humidity: implications for the pathogenesis of inflammatory dermatoses , 2001, The British journal of dermatology.

[20]  M. Denda.  Influence of dry environment on epidermal function. , 2000, Journal of dermatological science.

[21]  P. Elias,et al.  Epidermal pathogenesis of inflammatory dermatoses. , 1999, American journal of contact dermatitis : official journal of the American Contact Dermatitis Society.

[22]  P. Elias,et al.  Low humidity stimulates epidermal DNA synthesis and amplifies the hyperproliferative response to barrier disruption: implication for seasonal exacerbations of inflammatory dermatoses. , 1998, The Journal of investigative dermatology.

[23]  Peter M. Elias,et al.  Barrier recovery is impeded at neutral pH, independent of ionic effects: implications for extracellular lipid processing , 1998, Archives of Dermatological Research.

[24]  J. Youn,et al.  Factors Influencing Psoriasis: An Analysis Based upon the Extent of Involvement and Clinical Type , 1998, The Journal of dermatology.

[25]  T. Egelrud,et al.  Formation of active IL-1 beta from pro-IL-1 beta catalyzed by stratum corneum chymotryptic enzyme in vitro. , 1997, Acta dermato-venereologica.

[26]  P. Elias,et al.  Stratum corneum structure and function correlates with phenotype in psoriasis. , 1996, The Journal of investigative dermatology.

[27]  P. Elias,et al.  The epidermal hyperplasia associated with repeated barrier disruption by acetone treatment or tape stripping cannot be attributed to increased water loss , 1996, Archives of Dermatological Research.

[28]  I. Marenholz,et al.  Genes encoding structural proteins of epidermal cornification and S100 calcium-binding proteins form a gene complex ("epidermal differentiation complex") on human chromosome 1q21. , 1996, The Journal of investigative dermatology.

[29]  W. Sterry,et al.  Integrity of the permeability barrier regulates epidermal Langerhans cell density , 1996, The British journal of dermatology.

[30]  P. Elias,et al.  Barrier disruption stimulates interleukin-1 alpha expression and release from a pre-formed pool in murine epidermis. , 1996, The Journal of investigative dermatology.

[31]  S. Kang,et al.  Prolonged occlusion in the treatment of psoriasis: a clinical and immunohistologic study. , 1995, Journal of the American Academy of Dermatology.

[32]  B. Nickoloff,et al.  Perturbation of epidermal barrier function correlates with initiation of cytokine cascade in human skin. , 1994, Journal of the American Academy of Dermatology.

[33]  P. Elias,et al.  Cutaneous barrier perturbation stimulates cytokine production in the epidermis of mice. , 1992, The Journal of clinical investigation.

[34]  P. Elias,et al.  Barrier function regulates epidermal DNA synthesis. , 1991, The Journal of clinical investigation.

[35]  A. Gottlieb,et al.  Occlusive hydrocolloid dressings decrease keratinocyte population growth fraction and clinical scale and skin thickness in active psoriatic plaques. , 1990, Journal of dermatological science.

[36]  S. Friedman.  Management of psoriasis vulgaris with a hydrocolloid occlusive dressing. , 1987, Archives of dermatology.

[37]  E. Tschachler,et al.  Epithelial and Mesenchymal Cell Biology Epidermal Vascular Endothelial Growth Factor Production Is Required for Permeability Barrier Homeostasis , Dermal Angiogenesis , and the Development of Epidermal Hyperplasia Implications for the Pathogenesis of Psoriasis , 2010 .

[38]  D. Mischke,et al.  Normal psoriatic epidermis expression of hyperproliferation-associated keratins , 2004, Archives of Dermatological Research.

[39]  K. Kragballe,et al.  Remission and relapse of chronic plaque psoriasis treated once a week with clobetasol propionate occluded with a hydrocolloid dressing versus twice daily treatment with clobetasol propionate alone. , 2001, The Journal of dermatological treatment.